The clinical diagnostic testing services support and accelerate the market entry of new drugs, vaccines and antivirals, and assist in pre- and post marketing surveillance programs. Services are customized to specific needs, enabling maximum flexibility from day-to-day analysis to high throughput bulk analysis.read more
The clinical trial operations department is the latest addition to Viroclinics. It provides better logistics support for the pharmaceutical, biotechnology, and medical device industries and gives Viroclinics the opportunity to monitor the quality from the moment the sample is taken to the final test results.read more
Preclinical services include testing of efficacy, safety, PK and (immune) toxicology of drugs, antibodies, vaccines and antivirals targeting viral infectious diseases. The BSL-2 and BSL-3 facilities enable complicated experiments with highly pathogenic viruses. The qualified biotech staff and use of state of the art BSL2 and BSL3 animal facilities are key to a successful outcome of studies.read more
Assay innovation and the introduction of new tools keep analysis up to date with the increasingly demanding criteria for developing new therapeutic and prophylactic candidates up to market registration. Customized assay and protocol development is followed by standardization and validation procedures to allow for routine application in a clinical trial setting.read more
Viroclinics has adopted a high quality standard in all operations, testing procedures and reporting. The quality management system is based on NEN-EN-ISO 15189, GLP and expanded with elements of GCP, to comply with regulatory requirements and facilitate regulatory submissions.read more
Viroclinics participates in global surveillance programs to monitor and characterize novel virus threats to human and animal health (EMPERIE; EU FP-7). Additional research programs focus on genomics, discovery of biomarkers, correlates of protection and viral reference strain development.read more
HIGH QUALITY EXPERT VIROLOGY CONTRACT RESEARCH LABORATORY
Viroclinics Biosciences BV (Viroclinics) operates at a global level, being the preferred virology testing laboratory for several of the top-10 Biopharmaceutical companies. As a virology contract research organization, we serve the biopharmaceutical community with our preclinical, clinical diagnostic, assay development and clinical trial logistics services. Our extensive experience with clinical and preclinical studies for viruses, including our specialty in respiratory viruses, puts us at the forefront for supporting the development of vaccines, antibodies and antiviral compounds targeting viral infectious diseases. Our staff consists of over 140 well-trained, dedicated scientists and technical experts, and our projects are supported by an extensive network of key opinion leaders as consultants. Through an intense collaboration with the Erasmus MC Viroscience Lab, we offer the combined benefits of scientific knowledge and technical ability maintained at both laboratories. This enables Viroclinics Biosciences to support customers with the best virological knowledge available. Our uniquely consultative approach to business means we nurture deep client relationships in order to fully understand their needs and provide optimally customised research programs and project solutions.
BSL 2 AND BSL 3 FACILITIES AND HIGH QUALITY
Viroclinics Biosciences is a cutting edge lab service organisation with state of the art facilities including laboratory BSL 2 and BSL 3 facilities and a samples processing facility in New Jersey USA. Viroclinics has adopted a high quality standard in all operations, testing procedures and reporting. The quality management system is based on NEN-EN-ISO 15189, GLP and expanded with elements of GCP, to comply with regulatory requirements and facilitate regulatory submissions.
9 April 2020 The University of Queensland’s potential COVID-19 vaccine is entering an important new phase of testing with the live coronavirus to determine how effectively it induces protection against coronavirus infection. The UQ team will partner with the Dutch...read more
Subscribe to our newsletter for the latest insights on early stage, (pre)clinical research, cold chain logistics and assay development services.
• Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture.
• Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA.
• Comparison of the Abbott Realtime HIV-1 and HCV viral load assays with commercial competitor assays.
• Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA.
• Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.
We need you!
We are dynamic and diverse and are now offering a fascinating opportunity for a professional who likes to take initiative, is highly motivated to achieve, has focus on results, is flexible, and is willing to learn and cooperate. Currently we have vacancies for: